Merck & Co., Inc. vs Pfizer Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Merck & Co., Inc. is the larger company by market value: $359.8 B against $170.7 B for Pfizer Inc., 2.1 times as much (market caps of Oct 19, 2026 for Merck & Co., Inc. and Oct 30, 2026 for Pfizer Inc.).
- Merck & Co., Inc. had more revenue: $65.0 B against $62.6 B for Pfizer Inc., both in the year to December 2025.
- Merck & Co., Inc. earned more: net income of $18.3 B against $7.8 B for Pfizer Inc.
- Merck & Co., Inc. keeps more of each dollar of sales: a net margin of 28.1% against 12.4% for Pfizer Inc.
- Both employ 75,000 people. Each employee brings in about $866,813 of revenue at Merck & Co., Inc. and $834,387 at Pfizer Inc.
- On price to earnings, Merck & Co., Inc. trades at 146.7× and Pfizer Inc. at 42.3×: investors pay more for each dollar of Merck & Co., Inc.'s profit.
- Merck & Co., Inc.'s revenue grew faster in its latest fiscal year: +1.3% against -1.6% for Pfizer Inc.
- On the Piotroski F-score, a nine-point test of improving finances, Merck & Co., Inc. scores 4 and Pfizer Inc. 5.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Merck & Co., Inc. MRK · #41 in the world | Pfizer Inc. PFE · #127 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | Pharmaceutical |
| Founded | 1970 | 1849 |
| Size | ||
| Market cap | $359.8 B | $170.7 B |
| Revenue | $65.0 B | $62.6 B |
| Net income | $18.3 B▲ best | $7.8 B |
| Employees | 75,000 | 75,000 |
| Valuation | ||
| P/E ratio | 147× | 42.3× |
| Price to sales | 5.3× | 2.7× |
| Price to book | 6.8× | 2.0× |
| Free cash flow yield | 3.4% | 5.3%▲ best |
| Profitability | ||
| Gross margin | 74.8%▲ best | 74.3% |
| Net margin | 28.1%▲ best | 12.4% |
| Return on equity | 36.9%▲ best | 8.9% |
| Growth | ||
| Revenue growth | 1.3%▲ best | -1.6% |
| Revenue growth, 3 years a year | 3.1%▲ best | -14.8% |
| Earnings per share growth | 8.0%▲ best | -3.5% |
| Financial strength | ||
| Debt to equity | 0.9× | 0.7×▲ best |
| Cash | ||
| Free cash flow margin | 19.0%▲ best | 14.5% |
| Shareholder returns | ||
| Dividend yield | 2.3% | — |
| Shareholder yield | 3.7% | — |
| Strength scores | ||
| Piotroski F-score | 4 of 9 | 5 of 9▲ best |
| Altman Z-score zone | — | — |
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
Questions and answers#
Which is bigger, Merck & Co., Inc. or Pfizer Inc.?
Merck & Co., Inc. is the larger company by market value: $359.8 B against $170.7 B for Pfizer Inc., 2.1 times as much (market caps of Oct 19, 2026 for Merck & Co., Inc. and Oct 30, 2026 for Pfizer Inc.).
Which makes more money, Merck & Co., Inc. or Pfizer Inc.?
Merck & Co., Inc. had more revenue: $65.0 B against $62.6 B for Pfizer Inc., both in the year to December 2025. Merck & Co., Inc. earned more: net income of $18.3 B against $7.8 B for Pfizer Inc.
Which is more profitable, Merck & Co., Inc. or Pfizer Inc.?
Merck & Co., Inc. keeps more of each dollar of sales: a net margin of 28.1% against 12.4% for Pfizer Inc.
Which has more employees, Merck & Co., Inc. or Pfizer Inc.?
Both employ 75,000 people. Each employee brings in about $866,813 of revenue at Merck & Co., Inc. and $834,387 at Pfizer Inc.
Is Merck & Co., Inc. cheaper than Pfizer Inc.?
On price to earnings, Merck & Co., Inc. trades at 146.7× and Pfizer Inc. at 42.3×: investors pay more for each dollar of Merck & Co., Inc.'s profit. A lower multiple is not by itself a better buy: it also reflects expected growth, risk and accounting.
Which is growing faster, Merck & Co., Inc. or Pfizer Inc.?
Merck & Co., Inc.'s revenue grew faster in its latest fiscal year: +1.3% against -1.6% for Pfizer Inc.
Which is financially stronger, Merck & Co., Inc. or Pfizer Inc.?
On the Piotroski F-score, a nine-point test of improving finances, Merck & Co., Inc. scores 4 and Pfizer Inc. 5.